Healthcare / Drug Manufacturers - GeneralShenzhen
$40.92
+0.76 (+1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-93.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
194.9x
↑EV/EBITDA
62.1x
↑ROE
1.2%
↑Gross Margin
53.4%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.5%
FCF CAGR
—
FCF margin
-23.5%
FCF / Net income
-5.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $398.2M · net income $16.6M · FCF $-93.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $398.2M | $398.2M | $463.7M | $447.6M | $442.9M |
| Net Income | $16.6M | $16.6M | $60.4M | $77.0M | $91.3M |
| EBITDA | $68.8M | $68.8M | $112.6M | $114.6M | $132.3M |
| EPS | 0.15 | 0.15 | 0.56 | 0.76 | 1.12 |
| Gross Margin | 53.4% | 53.4% | 44.3% | 47.3% | 40.9% |
| Operating Margin | 11.2% | 11.2% | 13.3% | 14.7% | 22.3% |
| Net Margin | 4.2% | 4.2% | 13.0% | 17.2% | 20.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.03 | — | — |
| Current Ratio | 3.05 | 3.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-93.6M | $-93.6M | $-356.9M | $-33.1M | $84.8M |
| Returns | |||||
| ROE | 1.2% | 1.2% | 4.4% | 5.8% | 17.6% |
| Valuation | |||||
| P/E | 194.86 | 194.86 | 51.30 | 43.92 | — |
| EV/EBITDA | 62.08 | 62.08 | 26.36 | 26.68 | — |
| P/B | 3.33 | 3.33 | 2.28 | 2.54 | — |
| Growth & Yield | |||||
| Revenue Growth | -14.1% | -14.1% | 3.6% | 1.1% | — |
| EPS Growth | -73.2% | -73.2% | -26.3% | -32.1% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
189.3%
EPS terminal req.
$3.63
Spread vs growth
-262.5%
5Y implied EPS CAGR
96.5%
EPS terminal req.
$4.39
Spread vs growth
-169.7%
10Y implied EPS CAGR
47.0%
EPS terminal req.
$7.08
Spread vs growth
-120.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.6%
Start / end P/E
60.9x → 272.8x
EPS bridge
0.56 → 0.15
Residual
-254.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.